TG Therapeutics, Inc. (TGTX)
55.35
+2.01
(+3.77%)
USD |
NASDAQ |
Oct 09, 16:00
55.00
-0.35
(-0.63%)
After-Hours: 20:00
TG Therapeutics Cash from Operations (Quarterly) : 39.26M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 39.26M |
| March 31, 2026 | -17.89M |
| December 31, 2025 | 19.66M |
| September 30, 2025 | -23.15M |
| June 30, 2025 | 7.436M |
| March 31, 2025 | -28.72M |
| December 31, 2024 | -25.64M |
| September 30, 2024 | -12.20M |
| June 30, 2024 | 5.536M |
| March 31, 2024 | -8.207M |
| December 31, 2023 | -13.21M |
| September 30, 2023 | 83.70M |
| June 30, 2023 | -42.00M |
| March 31, 2023 | -59.90M |
| December 31, 2022 | -23.87M |
| September 30, 2022 | -34.50M |
| June 30, 2022 | -49.12M |
| March 31, 2022 | -68.69M |
| December 31, 2021 | -86.91M |
| September 30, 2021 | -67.20M |
| June 30, 2021 | -60.17M |
| March 31, 2021 | -81.36M |
| December 31, 2020 | -52.03M |
| September 30, 2020 | -56.53M |
| June 30, 2020 | -43.83M |
| Date | Value |
|---|---|
| March 31, 2020 | -62.12M |
| December 31, 2019 | -30.39M |
| September 30, 2019 | -33.20M |
| June 30, 2019 | -35.86M |
| March 31, 2019 | -33.35M |
| December 31, 2018 | -33.69M |
| September 30, 2018 | -33.01M |
| June 30, 2018 | -34.18M |
| March 31, 2018 | -28.04M |
| December 31, 2017 | -21.85M |
| September 30, 2017 | -22.78M |
| June 30, 2017 | -26.83M |
| March 31, 2017 | -22.30M |
| December 31, 2016 | -17.02M |
| September 30, 2016 | -15.04M |
| June 30, 2016 | -12.85M |
| March 31, 2016 | -16.67M |
| December 31, 2015 | -12.90M |
| September 30, 2015 | -10.66M |
| June 30, 2015 | -12.25M |
| March 31, 2015 | -8.882M |
| December 31, 2014 | -15.11M |
| September 30, 2014 | -8.051M |
| June 30, 2014 | -3.573M |
| March 31, 2014 | -8.329M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Krystal Biotech, Inc. | 74.79M |
| Vertex Pharmaceuticals, Inc. | 1.125B |
| SELLAS Life Sciences Group, Inc. | -7.588M |
| Travere Therapeutics, Inc. | 58.07M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 1.03M |
| Cash from Financing (Quarterly) | 0.085M |
| Free Cash Flow | 17.38M |
| Free Cash Flow Per Share (Quarterly) | 0.2478 |
| Free Cash Flow to Equity (Quarterly) | 38.09M |
| Free Cash Flow to Firm (Quarterly) | 51.57M |
| Free Cash Flow Yield | 0.20% |